Mindbloom, the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom.
Key Findings:
Largest study: The study reviewed data from 11,441 Mindbloom clients, making it the most comprehensive examination of ketamine therapy to date
Effectiveness: 62% of clients reported clinically-significant improvements in depression or anxiety, with 28% achieving remission
Rapid results: Significant symptom improvements were found after only four sessions
Safety: Fewer than 5% of clients reported adverse effects
Benefits of continued treatment: 84% of clients who experienced significant improvements in an initial round of treatment maintained improvements or recovered in a second round
